Sage Journals: Discover world-class research

Abstract

Objective

The optimal medical management strategy in the periprocedural period for patients undergoing carotid artery interventions is not well described. Renin-angiotensin-system blocking (RASB) agents are considered to be among the first line anti-hypertensive agents; however, their role in the perioperative period is unclear. The objective of this study was to examine the relationship between the use of RASB agents on periprocedural outcomes in patients undergoing carotid interventions—carotid endarterectomy (CEA), transfemoral carotid artery stenting (CAS), and transcervical carotid artery revascularization (TCAR).

Method

The Society for Vascular Surgery Quality Initiative database was queried for all patients undergoing CAS, CEA, and TCAR between 2003 and 2020. Patients were stratified into two groups based upon their use of RASB agents in the periprocedural period. The primary endpoint was periprocedural neurologic events (including both strokes and transient ischemic attacks (TIAs)). The secondary endpoints were peri-procedural mortality and significant cardiac events, including myocardial infarction, dysrhythmia, and congestive heart failure.

Results

Over 150,000 patients were included in the analysis: 13,666 patients underwent TCAR, 13,811 underwent CAS, and 125,429 underwent CEA for carotid artery stenosis. Overall, 52.2% of patients were maintained on RASB agents. Among patients undergoing CEA, patients on RASB agents had a significantly lower rate of periprocedural neurologic events (1.7% versus 2.0%, p =0.001). The peri-procedural neurological event rate in the TCAR cohort was similarly reduced in those treated with RASB agents, but did not reach statistical significance (2.0% vs 2.4%, p = 0.162). Among patients undergoing CAS, there was no difference in perioperative neurologic events between the RASB treated and untreated cohorts (3.4% vs 3.2%, p = 0.234); however, the use of RASB agents was significantly associated with lower mortality (1.2% vs 1.7%, p =0.001) with CAS. The use of preoperative RAS-blocking agents did not appear to affect the overall rates of adverse cardiac events with any of the three carotid intervention types, or periprocedural mortality following CEA or TCAR. On multivariable analysis, the use of RAS-blocking agents was independently associated with lower rates of post-procedural neurologic events in patients undergoing CEA (OR 0.819, CI 0.747–0.898; p = 0.01) and TCAR (OR 0.869, CI 0.768–0.984; p = 0.026), but not in those undergoing CAS (OR 0.967, CI 0.884–1.057; p = 0.461).

Conclusion

The use of peri-procedural RASB agents was associated with a significantly decreased rate of neurologic events in patients undergoing both CEA and TCAR. This effect was not observed in patients undergoing CAS. As carotid interventions warrant absolute minimization of perioperative complications in order to provide maximum efficacy with regard to stroke protection, the potential neuro-protective effect associated with RASB agents use following CEA and TCAR warrants further examination.

Keywords

carotid endarterectomy renin angiotensin system blood pressure carotid stenting vascular quality initiative database

Get full access to this article

View all access options for this article.

References

Towne

Bernhard

. The relationship of postoperative hypertension to complications following carotid endarterectomy. Surgery 1980; 88(4): 575–580.

McCrory

Goldstein

Samsa

, et al. Predicting complications of carotid endarterectomy. Stroke 1993; 24: 1285–1291.

Obeid

Arhuidese

Gaidry

, et al. Beta-blocker use is associated with lower stroke and death after carotid artery stenting. J Vasc Surg 2016; 63(2): 363–369.

Brott

Hobson

2nd Howard

, et al. CREST Investigators. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363(1): 11–23.

Abou-Chebl

Reginelli

Bajzer

, et al. Intensive treatment of hypertension decreases the risk of hyperperfusion and intracerebral hemorrhage following carotid artery stenting. Catheter Cardiovasc Interv 2007; 69(5): 690–696.

Mostafaie

Bedenis

Harrington

. Beta-adrenergic blockers for perioperative cardiac risk reduction in people undergoing vascular surgery. Cochrane Database Syst Rev 2015; 1: CD006342.

Hajibandeh

Antoniou

, et al. Effect of beta-blockers on perioperative outcomes in vascular and endovascular surgery: a systematic review and meta-analysis. Br J Anaesth 2017; 118(1): 11–21.

Whelton

Carey

Aronow

, et al. ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol 2018 2017; 71: e127–e248.

Ostergren

Sleight

Dagenais

, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004; 25: 17–24.

10.

Perler

. The effect of statin medications on perioperative and long-term outcomes following carotid endarterectomy or stenting. Semin Vasc Surg 2007; 20(4): 252–258.

11.

Hobson

2nd Krupski

Weiss

. Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis. J Vasc Surg 1993; 17(2): 257–263, discussion 263-5.

12.

Steely

Callas

Bertges

. Renin-angiotensin-aldosterone-system inhibition is safe in the preoperative period surrounding carotid endarterectomy. J Vasc Surg 2016; 63(3): 715–721.

13.

Fukuhara

Geary

Diz

, et al. Angiotensin-converting enzyme expression in human carotid artery atherosclerosis. Hypertension 2000; 35(1 Pt 2): 353–936.

14.

Mukherjee

Yadav

. Carotid artery intimal-medial thickness: indicator of atherosclerotic burden and response to risk factor modification. Am Heart J 2002; 144: 753–759.37.

15.

Sattler

Woodrum

Galili

, et al. Concurrent treatment with renin-angiotensin system blockers and acetylsalicylic acid reduces nuclear factor B activation and C-reactive protein expression in human carotid artery plaques. Stroke 2005; 36: 1420–1438.

16.

Rice

Lumsden

. Optimal medical management of peripheralarterial disease. Vasc Endovasc Surg 2006; 40: 312–317.

17.

Robinson

Dawson

Eames

, et al. Cardiac baroreceptor sensitivity predicts long-term outcome after acute ischemic stroke. Stroke 2003; 34: 705–712.

18.

Moulakakis

Mylonas

Sfyroeras

, et al. Hyperperfusion syndrome after carotid revascularization. J Vasc Surg 2009; 49(4): 1060–1068.

19.

Farooq

Goshgarian

Min

, et al. Pathophysiology and management of reperfusion injury and hyperperfusion syndrome after carotid endarterectomy and carotid artery stenting. Exp Transl Stroke Med 2016; 8(1): 7.

20.

Asiddao

Donegan

Whitesell

, et al. Factors associated with perioperative complications during carotid endarterectomy. Anesth Analg 1982; 61(8): 631–637.

21.

Dakour Aridi

Paracha

Nejim

, et al. Anesthetic type and hospital outcomes after carotid endarterectomy from the vascular quality initiative database. J Vasc Surg 2018; 67(5): 1419–1428.

22.

Malas

Dakour-Aridi

Wang

, et al. Transcarotid artery revascularization versus transfemoral carotid artery stenting in the Society for vascular surgery vascular quality initiative. J Vasc Surg 2019; 69(1): 92–103.e2.

23.

Calvillo-King

Xuan

Zhang

, et al. Predicting risk of perioperative death and stroke after carotid endarterectomy in asymptomatic patients: derivation and validation of a clinical risk score. Stroke 2010; 41(12): 2786–2794.

24.

Dimic

Markovic

Vasic

, et al. Impact of diabetes mellitus on early outcome of carotid endarterectomy. Vasa 2019; 48(2): 148–156.

25.

Malas

Dakour-Aridi

Wang

, et al. Transcarotid artery revascularization versus transfemoral carotid artery stenting in the Society for Vascular Surgery Vascular Quality Initiative. J Vasc Surg 2019; 69(1): 92–103, e2.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.38 MB